GSK
GSK plc is a British biopharmaceutical enterprise that discovers, develops, and manufactures specialty medicines and vaccines globally. The company concentrates its operational activities across three core therapeutic product areas: Vaccines, Specialty Medicines, and General Medicines. Its key commercial product portfolio includes innovative vaccines such as Shingrix for shingles and Arexvy for RSV, alongside prescription medicines for HIV, oncology, respiratory, and infectious diseases. Principal revenue drivers consist of commercial sales of proprietary vaccines and prescription pharmaceuticals, supplemented by royalty revenues and strategic product licensing partnerships. GSK serves broad global end markets encompassing hospital procurement groups, government immunization programs, retail pharmacies, healthcare providers, and patients across North America, Europe, and international markets. The corporation holds a leading market position as one of the world's largest vaccine manufacturers and biopharmaceutical companies by research investment and annual revenues. Headquartered in London, United Kingdom, the company's common stock is primary listed on the London Stock Exchange under the ticker symbol GSK, with American Depositary Receipts listed on the New York Stock Exchange.
131 of the funds FundTelligence covers report a position in GSK.
- Legal name
- GSK PLC
- Sector
- Health Care
- Country
- United Kingdom
- Funds holding it
- 131
- Exposure themes
- Multiple, Treatment, Women's Health
Funds holding GSK
- BlackRock iShares MSCI Europe Health Care Sector UCITS ETF — BlackRock · 5.18 % (full portfolio disclosed, October 2026)
- Fondsfinans Global Helse — Fondsfinans · 3.66 % (full portfolio disclosed, October 2026)
- Schroder ISF Global Sustainable Value — Schroders · 3.62 % (full portfolio disclosed, June 2026)
- DWS Invest CROCI Sectors Plus — DWS · 3.39 % (full portfolio disclosed, June 2026)
- iShares UK Index Fund (IE) — BlackRock · 3.19 % (largest positions only, September 2026)
- Wellington Global Health Care Equity Fund — Wellington · 2.72 % (largest positions only, October 2026)
- Sparinvest European Value — Sparinvest · 2.65 % (full portfolio disclosed, September 2026)
- Schroder ISF Healthcare Innovation — Schroders · 2.63 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 131 funds holding it.